ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2153 entries already.
Entries by Thomas Gabrielczyk
Four new autoantigens trigger multiple sclerosis
Swiss and Swedish researchers have uncovered four previously unkown autoantigens that trigger multiple sclerosis in mice.
TWB partners with Processium and Syngulon
Industrial biotech project managment specialist Toulouse White Biotech (TWB) has joined forces with process developer Processium and industrial synbio start-up Syngulon.
Meat consumption must fall by at least 75 percent
If our planet is to continue feeding us in the future, rich countries must significantly reduce their meat consumption by at least 75% suggests a new study by German researchers.
Vigeneron updates gene therapy collab with Daiichi Sankyo
ViGeneron and Daiichi Sankyo have agreed a follow-on collaboration to evaluate vgAAVs as vectors for Daiichi Sankyo’ novel treatment of prevalent eye diseases.
Single-use market to reach $20.8bn by 2026
Analysts from Markets & Markets today released the report "Single use Bioprocessing Market by Product.
Study shows advantages of cellular agriculture
Novel foods derived from cell culture instead of animals reduce the environmental impact of diets, water and land use by 80%, report Finnish researchers.
EMA delays Valneva vaccine approval
The approval of Valneva’s Corona vaccine is delaying. The European Medicines Agency’s CHMP requested additional data.
Mimetas BV participating in €325m cancer funding
Organ-on-chip disease model specialist Mimentas BV participates in a €325m funding to accelerate preclinical cancer R&D in the Netherlands.
Hansa Biopharma’s imlifidase advances to Phase III testing
The US Food & Drug Administration has given the green light for Phase III testing of Hansa Biopharma’s imlifidase in anti-GBM disease.